Úvod: Fibróza tkaniva spôsobená zápalovými procesmi súvisí s aktivitou matrix metaloproteináz (MMPs) a ich inhibítorov (TIMPs). Poznatky o expresii týchto enzýmov u pľúcnej sarkoidózy (PS) sú limitované. Cieľom tejto štúdie bolo stanoviť expresiu MMP2, TIMP1 a TIMP2 na úrovni mesengerovej RNA. Metódy: Na posúdenie relatívnej expresie MMP2, TIMP1 a TIMP2 bola použitá kvantitatívna PCR. Hodnoty boli merané vo vzorkách od 18 pacientov s PS a 19 pacientov v kontrolnej skupine. Výsledky: Relatívna expresia bola zvýšená u pacientov s PS pre všetky tri študované gény. Medzi jednotlivými štádiami ochorenia bolo pozorované zvýšenie len pre TIMP2, a to medzi štádiom II a III-IV. V pomere expresií bolo namerané zvýšenie pre MMP2/TIMP1 a MMP2/TIMP2 v provnaní s kontrolnou skupinou. Za signifikantné boli považované hodnoty p0,05. Záver: Táto štúdia prináša nové znalosti o prítomnosti MMP2, TIMP1 a TIMP2 u pľúcnej sarkoidózy. Výsledky našich pozorovaní by mali byť potvrdené na väčšej skupine pacientov, ktorá by taktiež potvrdila expresiu týchto génov v jednotlivých štádiach ochorenia.Background and objective: Tissue fibrosis caused by inflammatory disease is often connected to the activity of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs). Information about expression of those enzymes in pulmonary sarcoidosis (PS) is limited. The objective of this clinical study was to qualify the expression of MMP2, TIMP1 and TIMP2 on mRNA level. Methods: Quantitative PCR was used for the assessment of relative expression of MMP2, TIMP1 and TIMP2. Results were measured in BAL samples from 18 patients with PS and 19 patients in the control group. Results: Relative expression in BAL samples was increased in PS patients for all 3 genes. Between stages of the disease, only TIMP2 was increased in stage II compared to stages III-IV. For expression ratios there was increase in MMP2/TIMP1 and MMP2/TIMP2 compared to control group. Results, that were p0,05, were considered significant. Concusions: This clinical study brings new knowledge of the activity of MMP2, TIMP1 and TIMP2 in pulmonary sarcoidosis. Results of our observations should be confirmed in a bigger clinical study with more patients, that would also confirm the expression of these genes between individual stages.